Potent anti-tumor activity of the AXL-targeted antibody-drug conjugate, mipasetamab uzoptirine (ADCT-601), in preclinical models of adenoid cystic carcinoma
{{output}}
Adenoid cystic carcinoma (ACC) is a rare salivary gland malignancy with no FDA-approved systemic therapies and limited benefit from conventional treatments. Proteogenomic profiling has revealed consistent overexpression of AXL, providing a compelling rationale... ...
